LTFU PAH sotatercept study MK-7962-004 (Obsolete Identifier: NCT04796337) has been incorporated into the current MK-7962-038 (NCT07218029) study for administrative reasons. The MK-7962-004 study is no longer enrolling participants and will be formally closed. Only those who participated in MK-7962-004 may be eligible to continue into MK-7962-038.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has completed their current respective PAH sotatercept clinical study and its requirements, and must not have discontinued early
Is willing to adhere to the study visit schedule, and understands and will comply with all protocol requirements
Must have the ability to understand and provide documented informed consent
You may not be if
Did not participate in a sotatercept PAH parent study
Missed more than the equivalent of 4 consecutive doses between the end of parent study and the start of this study.
Presence of an ongoing serious adverse event that occurred during a PAH sotatercept clinical study that is assessed to be possibly or probably related to sotatercept
Is a female who is pregnant or breastfeeding
Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study
Is currently enrolled in another investigational product study other than a sotatercept study
